Market research
IVA.PA Inventiva S.A
PA EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 950M
- P/E ratio
- Not available
- Analyst target
- 9.6344
- Dividend yield
- Not available
- Beta
- 0.91
Profile
Company facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0013233012
- Market cap
- 950M
- P/E ratio
- Not available
- Analyst target
- 9.6344
- Dividend yield
- Not available
- Beta
- 0.91
About
About Inventiva S.A
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. Inventiva S.A. was incorporated in 2011 and is headquartered in Daix, France.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the IVA.PA discussion.
5 years, 4 months ago
Inventiva S.A is currently in a long term downtrend where the price is trading 2.2% below its 200 day moving average.
From a valuation standpoint, the stock is 308.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 1116.4.
Inventiva S.A's total revenue sank by 0.0% to $4M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 143.5% to $-12M since the same quarter in the previous year.
Based on the above factors, Inventiva S.A gets an overall score of 0/5.